BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Krystal Biotech\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Krystal Biotech\, Inc.'s drugs ru
 n\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06228326-2575@assetmemo.bio
DTSTAMP:20261121T005930Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:KB707: Phase 1/2 readout est. (NCT06228326)
DESCRIPTION:KB707\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Study
  Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Af
 fecting the Lungs\nEstimated primary completion: February 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/kb707#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06228326
URL:https://assetmemo.bio/drug/kb707#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05970497-2575@assetmemo.bio
DTSTAMP:20261121T005930Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:KB707: Phase 1/2 readout est. (NCT05970497)
DESCRIPTION:KB707\, phase 1/2.\nStudy: A Study Assessing KB707 for the Trea
 tment of Locally Advanced or Metastatic Solid Tumors\nEstimated primary co
 mpletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 kb707#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05970497
URL:https://assetmemo.bio/drug/kb707#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
